By Counterforce Health Team in Increlex (mecasermin) —

Myths vs. Facts: Getting Increlex (mecasermin) Covered by Humana in North Carolina

Quick Answer: Humana covers Increlex (mecasermin) under Medicare Part B with strict prior authorization requiring severe primary IGF-1 deficiency diagnosis (IGF-1 ≤-3 SD), pediatric endocrinologist evaluation, and hypoglycemia monitoring plan. If denied, you have 65 days to appeal internally, then can request North Carolina's free Smart NC external review. Start by gathering IGF-1 labs, growth charts, and GH stimulation test results.

Table of Contents

Why Myths About Increlex Coverage Persist

When your child needs Increlex (mecasermin) for severe primary IGF-1 deficiency, misinformation can delay critical treatment. Many families believe common myths about insurance coverage that simply aren't true—especially for rare disease medications costing over $16,000 per vial.

These misconceptions often stem from well-meaning advice shared in parent support groups or outdated information from previous insurance experiences. The reality is that Humana's coverage criteria for Increlex are highly specific, and understanding the facts can make the difference between approval and months of appeals.

Let's separate myth from reality so you can navigate Humana's process effectively in North Carolina.

Common Myths vs. Facts

Myth 1: "If my pediatric endocrinologist prescribes Increlex, Humana has to cover it"

Fact: Humana requires strict prior authorization regardless of who prescribes Increlex. Coverage depends on meeting specific medical necessity criteria, not just having a specialist's prescription. According to Humana's clinical guidelines, patients must demonstrate severe primary IGF-1 deficiency with IGF-1 levels ≤3 standard deviations below normal, height ≤-3.0 SD, and normal growth hormone stimulation tests.

Myth 2: "Growth hormone deficiency and IGF-1 deficiency are covered the same way"

Fact: These are completely different conditions with separate coverage pathways. Increlex is only approved for severe primary IGF-1 deficiency—when the body can't use growth hormone effectively. If your child has growth hormone deficiency instead, Humana covers different medications like somatropin, not Increlex.

Myth 3: "Humana covers all specialty medications at the same cost-sharing level"

Fact: Increlex is typically placed on Humana's highest specialty tier with 25-40% coinsurance, meaning families pay thousands out-of-pocket even with coverage. Unlike standard medications with fixed copays, specialty drugs use percentage-based cost-sharing that can reach $4,000-6,000 per month.

Myth 4: "Prior authorization is just paperwork—it doesn't affect real coverage decisions"

Fact: Prior authorization directly determines whether Humana covers Increlex. In 2023, Humana's Medicare Advantage plans had a 3.5% denial rate for prior authorization requests. When denials occur for specialty medications like Increlex, they're usually based on missing diagnostic documentation or failure to meet strict lab criteria.

Myth 5: "If Humana denies coverage, there's nothing we can do"

Fact: North Carolina offers robust appeal rights through both Humana's internal process and the state's Smart NC external review program. The NC Department of Insurance reports that external reviews overturned 32.4% of insurance denials in their most recent published data, with expedited decisions available within 72 hours for urgent cases.

Myth 6: "We have to try cheaper alternatives first before Humana will cover Increlex"

Fact: Increlex doesn't have therapeutic alternatives because it treats a specific genetic condition. However, Humana does require documentation that your child truly has severe primary IGF-1 deficiency rather than growth hormone deficiency (which would be treated with different, less expensive medications).

Myth 7: "Medicare and commercial Humana plans have the same Increlex coverage"

Fact: Humana Medicare Advantage covers Increlex under Part B (medical benefit), while commercial plans may place it under pharmacy benefits with different prior authorization requirements and appeal timelines. Medicare patients have 65 days to appeal denials, while commercial plan timelines vary.

What Actually Influences Humana's Approval

Humana's Increlex coverage decisions center on three key factors: diagnostic precision, safety documentation, and regulatory compliance.

Diagnostic Requirements:

  • IGF-1 levels ≤3 standard deviations below age/sex norms
  • Height standard deviation score ≤-3.0
  • Normal growth hormone stimulation test (peak ≥7-10 ng/mL)
  • Age 2-18 years with open growth plates
  • Exclusion of secondary causes (malnutrition, chronic disease)

Safety Documentation: Humana requires a detailed hypoglycemia monitoring plan because Increlex carries significant risk. Your submission must include protocols for glucose monitoring, meal timing (±20 minutes of injection), dose titration starting at 0.04 mg/kg twice daily, and emergency glucagon availability.

Clinical Documentation: The strongest approvals include pediatric endocrinologist consultation notes, complete growth charts, bone age X-rays, and prior therapy history. Counterforce Health helps families compile this evidence by analyzing denial letters and identifying exactly which documents Humana requires for approval.

Mistakes to Avoid

1. Submitting Incomplete Lab Work

Don't assume any IGF-1 test is sufficient. Humana requires age-specific, standardized IGF-1 measurements with clear documentation that levels are ≤3 SD below normal. Many denials occur because labs don't include proper reference ranges or were drawn at inappropriate times.

2. Missing the Safety Plan

Never submit a prior authorization without a detailed hypoglycemia monitoring protocol. Include specific plans for glucose checking, meal timing, dose escalation, and emergency management. This isn't optional—it's a regulatory requirement.

3. Confusing Appeal Deadlines

Humana Medicare patients have 65 days to file appeals, but expedited appeals must be requested within 72 hours if delay could jeopardize health. Don't wait until the standard deadline if your child needs urgent treatment.

4. Using the Wrong Submission Method

Submit through CoverMyMeds or Humana's provider portal rather than fax when possible. Electronic submissions provide tracking and faster processing than paper forms that can get lost.

5. Skipping Peer-to-Peer Review

If Humana's initial review is negative, request a peer-to-peer consultation between your pediatric endocrinologist and Humana's medical director. These physician-to-physician discussions often resolve complex cases within 1-2 business days.

Quick Action Plan

Step 1: Gather Documentation Today

Collect your child's complete medical records including:

  • IGF-1 lab results with reference ranges
  • Growth charts showing height ≤3rd percentile
  • Growth hormone stimulation test results
  • Pediatric endocrinologist consultation notes
  • Bone age X-ray reports

Step 2: Verify Your Humana Plan Type

Check your insurance card to determine if you have Medicare Advantage (appeals to Humana, then CMS) or commercial coverage (appeals to Humana, then North Carolina external review). The process and timelines differ significantly.

Step 3: Submit Complete Prior Authorization

Work with your pediatric endocrinologist to submit a comprehensive prior authorization including all diagnostic criteria, safety monitoring plans, and clinical rationale. Use electronic submission methods when available.

From our advocates: We've seen families successfully overturn Increlex denials by focusing on the safety monitoring plan. One case involved a 4-year-old whose initial denial was overturned after the family provided detailed glucose monitoring logs and emergency protocols. The key was demonstrating that hypoglycemia risks were manageable with proper oversight.

North Carolina External Review Rights

If Humana denies your Increlex appeal, North Carolina residents have powerful external review rights through Smart NC.

Eligibility:

  • State-regulated commercial plans (not Medicare Advantage)
  • Completed Humana's internal appeals process
  • Denial based on medical necessity or experimental treatment

Process:

  1. Submit external review request to Smart NC within 120 days
  2. Independent review organization evaluates your case
  3. Binding decision within 45 days (72 hours for expedited)

Success Factors: Include comprehensive clinical documentation, specialty guidelines supporting Increlex use, and evidence that your child meets FDA-approved indications. Smart NC staff provide free assistance with form completion and document gathering.

Contact Smart NC: 1-855-408-1212 for free advocacy support.

Resources and Next Steps

Humana Resources:

  • Medicare Drug List Tool - verify formulary status
  • CoverMyMeds portal - electronic prior authorization submission
  • Humana customer service: number on your insurance card

North Carolina Support:

Clinical Resources:

Technology Assistance: Counterforce Health specializes in turning insurance denials into targeted appeals for specialty medications like Increlex. Their platform analyzes denial letters and creates evidence-backed rebuttals aligned to Humana's specific requirements, helping families navigate complex prior authorization and appeal processes more effectively.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual medical circumstances and specific insurance plan terms. Consult your healthcare provider and insurance plan documents for personalized guidance. For official North Carolina insurance regulations and appeal rights, visit the NC Department of Insurance.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.